Reina Haque1, Stephen K Van Den Eeden2, Lauren P Wallner3, Kathryn Richert-Boe4, Bhaskar Kallakury5, Renyi Wang3, Sheila Weinmann4. 1. Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Reina.Haque@kp.org. 2. Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. 3. Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. 4. Center for Health Research, Kaiser Permanente Northwest, Portland, OR, United States. 5. Georgetown University, Department of Pathology, Washington, DC, United States.
Abstract
OBJECTIVES: Inconsistent evidence exists on whether obesity is associated with an increased risk of prostate cancer death post-radical prostatectomy. We examined data from three large health plans to evaluate if an increased body mass index (BMI) at prostate cancer diagnosis is related to prostate cancer mortality SUBJECTS AND METHODS: This population-based case-control study included 751 men with prostate cancer who underwent radical prostatectomy. Cases were men who died due to prostate cancer (N=323) and matched controls (N=428). We used multivariable logistic regression models to assess the association between BMI at diagnosis and prostate cancer mortality, adjusted for Gleason score, PSA, tumour characteristics, and matching factors. RESULTS: Study subjects were classified into the following BMI (kg/m2) categories: healthy (18.5-24.9), overweight (25-29.9) and obese (≥30). Nearly 43% of the participants had a BMI ≥25 at diagnosis. A higher fraction of cases (30%) were obese compared to controls (22%). Overall, obese men had more than a 50% increase in prostate cancer mortality (adjusted odds ratio=1.50 [95% CI, 1.03-2.19]) when compared to men with healthy BMI. After stratifying by Gleason score, the odds of mortality generally rose with increasing BMI. The strongest effect was observed in the Gleason score 8+ category (2.37, 95% CI: 1.11-5.09). These associations persisted after adjusting for PSA at diagnosis and other tumour characteristics. CONCLUSIONS: These results suggest that BMI at diagnosis is strongly correlated with prostate cancer mortality, and that men with aggressive disease have a markedly greater odds of death if they are overweight or obese.
OBJECTIVES: Inconsistent evidence exists on whether obesity is associated with an increased risk of prostate cancer death post-radical prostatectomy. We examined data from three large health plans to evaluate if an increased body mass index (BMI) at prostate cancer diagnosis is related to prostate cancer mortality SUBJECTS AND METHODS: This population-based case-control study included 751 men with prostate cancer who underwent radical prostatectomy. Cases were men who died due to prostate cancer (N=323) and matched controls (N=428). We used multivariable logistic regression models to assess the association between BMI at diagnosis and prostate cancer mortality, adjusted for Gleason score, PSA, tumour characteristics, and matching factors. RESULTS: Study subjects were classified into the following BMI (kg/m2) categories: healthy (18.5-24.9), overweight (25-29.9) and obese (≥30). Nearly 43% of the participants had a BMI ≥25 at diagnosis. A higher fraction of cases (30%) were obese compared to controls (22%). Overall, obesemen had more than a 50% increase in prostate cancer mortality (adjusted odds ratio=1.50 [95% CI, 1.03-2.19]) when compared to men with healthy BMI. After stratifying by Gleason score, the odds of mortality generally rose with increasing BMI. The strongest effect was observed in the Gleason score 8+ category (2.37, 95% CI: 1.11-5.09). These associations persisted after adjusting for PSA at diagnosis and other tumour characteristics. CONCLUSIONS: These results suggest that BMI at diagnosis is strongly correlated with prostate cancer mortality, and that men with aggressive disease have a markedly greater odds of death if they are overweight or obese.
Authors: Carmen Rodriguez; Stephen J Freedland; Anusila Deka; Eric J Jacobs; Marjorie L McCullough; Alpa V Patel; Michael J Thun; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12-19 Impact factor: 4.254
Authors: William W Bassett; Matthew R Cooperberg; Natalia Sadetsky; Stefanie Silva; Janeen DuChane; David J Pasta; June M Chan; Jason W Anast; Peter R Carroll; Christopher J Kane Journal: Urology Date: 2005-11 Impact factor: 2.649
Authors: Zhihong Gong; Marian L Neuhouser; Phyllis J Goodman; Demetrius Albanes; Chen Chi; Ann W Hsing; Scott M Lippman; Elizabeth A Platz; Michael N Pollak; Ian M Thompson; Alan R Kristal Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Alan W Partin Journal: J Urol Date: 2006-10 Impact factor: 7.450
Authors: Mari-Anne Rowlands; David Gunnell; Ross Harris; Lars J Vatten; Jeff M P Holly; Richard M Martin Journal: Int J Cancer Date: 2009-05-15 Impact factor: 7.396
Authors: Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Daniel Shepshelovich; Wei Xu; Lin Lu; Aline Fares; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Xifeng Wu; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; M Catherine Brown; Geoffrey Liu; Rayjean J Hung Journal: J Thorac Oncol Date: 2019-06-01 Impact factor: 15.609
Authors: Mohamad Dave Dimachkie; Misty D Bechtel; Hilary L Robertson; Carrie Michel; Eugene K Lee; Debra K Sullivan; Prabhakar Chalise; J Brantley Thrasher; William P Parker; Andrew K Godwin; Harsh B Pathak; John DiGiovanni; Nitin Shivappa; James R Hébert; Jill M Hamilton-Reeves Journal: Urol Oncol Date: 2021-02-07 Impact factor: 2.954
Authors: Han Jin Cho; Gyoo Taik Kwon; Heesook Park; Hyerim Song; Ki Won Lee; Jung-In Kim; Jung Han Yoon Park Journal: Nutrients Date: 2015-04-09 Impact factor: 5.717
Authors: Amy Schleper; Debra K Sullivan; J Brantley Thrasher; Jeffrey M Holzbeierlein; Jennifer Klemp; Christie Befort; Jill M Hamilton-Reeves Journal: Cancer Clin Oncol Date: 2016-05
Authors: Craig A Glastonbury; Ana Viñuela; Alfonso Buil; Gisli H Halldorsson; Gudmar Thorleifsson; Hannes Helgason; Unnur Thorsteinsdottir; Kari Stefansson; Emmanouil T Dermitzakis; Tim D Spector; Kerrin S Small Journal: Am J Hum Genet Date: 2016-09-01 Impact factor: 11.025